Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20281224 | 0.81 | POLB (0.48) | MAPK1POLBMAPTESR2GPR119 | |
| SCHEMBL28613166 | 0.80 | PIK3CA (0.38) | NAMPTGRM5 | |
| SCHEMBL22743899 | 0.80 | MAPT (0.45) | MAPK1POLBMAPTESR2GPR119 | |
| SCHEMBL11985662 | 0.80 | MAPK1 (0.57) | MAPK1ESR2GPR119NR1H2USP2 | |
| SCHEMBL31046947 | 0.80 | MAPK1 (0.57) | MAPK1ESR2GPR119NR1H2USP2 | |
| SCHEMBL30098007 | 0.80 | ESR2 (0.50) | MAPK1POLBMAPTESR2NR1H2 | |
| SCHEMBL2891547 | 0.80 | ESR2 (0.50) | MAPK1POLBMAPTESR2NR1H2 | |
| SCHEMBL3793892 | 0.79 | LTA4H (0.39) | NAMPT | |
| SCHEMBL22743885 | 0.79 | POLB (0.45) | MAPK1POLBMAPTESR2GPR119 | |
| SCHEMBL21800527 | 0.79 | RIPK1 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3766878-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| EP-3766878-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3307729-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-09-02 | — | — | EP | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20180169110-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| WO-2018104766-A1 | 3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | WO | disclosed |
| EP-3307729-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2018863-B9 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2015-02-18 | — | — | EP | disclosed |
| EP-2018863-B1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2742936-A1 | Fused heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| EP-2727585-A1 | In-vivo screening method | Takeda Pharmaceutical Company Limited (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SHIRAI JUNYA (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8158617-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| EP-2018863-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | MAPK1 1614/4885POLB 4618/4885MAPT 4568/4885 |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | HTR2C, HTR3C, HTR3B | MAPK1 1614/4885POLB 4618/4885MAPT 4568/4885 |
| US-10272095-B2 | NRF2 regulators | NFE2L2, KEAP1, NQO1 | MAPK1 3198/4885POLB 2067/4885MAPT 2064/4885 |
| US-20190224212-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | MAPK1 3198/4885POLB 2067/4885MAPT 2064/4885 |
| US-20180169110-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | MAPK1 3198/4885POLB 2067/4885MAPT 2064/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | MAPK1 1614/4885POLB 4618/4885MAPT 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.